Sollentuna

This research aims to describe the characteristics, treatment patterns, and clinical outcomes of patients receiving palbociclib in Swedish clinical practice. The study focuses on individuals with metastatic breast cancer who are treated with this medication. It observes real-world use and results of palbociclib treatment over time. Participants receive palbociclib as part of their combination treatment regimen. The study tracks patients who have filled at least one prescription for palbociclib, monitoring how the drug is used in routine care. There are no comparator groups or additional interventions besides the treatment with palbociclib. During the study period from January 2017 to September 2020, researchers collect data on the proportion of patients continuing treatment with palbociclib. The study involves reviewing treatment records and clinical outcomes to understand how patients respond to therapy in everyday practice. Participation includes ongoing observation of treatment adherence and effectiveness over this timeframe.